跳至主要内容
临床试验/NCT01979874
NCT01979874已完成2 期

The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation II

University of California, San Francisco2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2014年2月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
26
试验地点
2
主要终点
Systemic Inflammatory bio-markers

研究概览

简要总结

Investigators hypothesize that high-dose n-3 polyunsaturated fatty acids (PUFA) oral supplementation will improve systemic inflammation, vascular function, and symptomatic status of patients with PAD. Investigators will explore novel mechanistic pathways by which n-3 PUFA affect PAD, evaluating the role of specialized lipid mediators involved in the resolution of inflammation.

详细描述

The OMEGA-PAD II trial will be a 1:1 randomized, double-blinded trial comparing oral supplementation of n-3 PUFA (4.4g/day) to placebo in claudicants (Rutherford stage 1-3) for 3 months. Eligible patients will be screened according to specified inclusion and exclusion criteria. All patients will be treated per our current practice as reflected in the American Heart Association Practice guidelines on PAD. Blood draws, vascular function testing and 6-minute walking tests will be performed at baseline and after 3 months. n-3 PUFA supplementation will be achieved with 4 capsules of Pro-Omega twice daily (Nordic Naturals, Watsonville, California, USA), corresponding to a total of 4.4g/day. Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. The placebo group will take the same number of capsules containing inactive substance (soybean; Nordic Naturals), designed to be the same color and shape as the treatment capsules.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
50 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Intermittent claudication (Rutherford 1-3)
  • One of the following:
  • Resting or exercise ankle-brachial index (ABI) <0.9
  • toe pressure < 70 mm Hg
  • documentation on imaging of greater than or equal to 50% stenosis in segments of aortoiliac arteries, femoral arteries, or tibial arteries
  • Age 50 and more

排除标准

  • Critical limb ischemia
  • Hypersensitivity/allergies to fish or seafood
  • Already on n-3 PUFA or equivalent
  • Significant renal, hepatic, and inflammatory disease
  • Concurrent severe infections
  • Acute illness (myocardial infarction, stroke, major surgery within 30 days)
  • Receiving immunosuppressive medications or steroids

研究组 & 干预措施

Pro-Omega

Experimental

High-dose, short-duration dietary omega-3 fatty acids supplementation; 325mg of EPA and 225mg of DHA per capsule. 4.4gm/day x 3 months (Nordic Naturals, Watsonville, CA, USA)

干预措施: Pro-Omega (Dietary Supplement)

Placebo

Placebo Comparator

Pro-Omega Placebo soybean capsules (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months

干预措施: ProOmega Placebo (Other)

结局指标

主要结局

Systemic Inflammatory bio-markers

时间窗: 3 months

reduce circulating pro-inflammatory markers (PIMs) and increase pro-resolution mediators (PRMs) assayed using targeted metabolo-lipidomics, increase PRM production within peripheral circulating monocytes.

次要结局

  • Endothelial Function(3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验